Industry updates from the field of stem cell research and regenerative medicine in September 2022
Abstract
Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in September 2022.
Tweetable abstract
Regenerative medicine industry news digest, September 2022
References
- 1. Arsenal Biosciences. Arsenal Biosciences Announces Joint Discovery Collaboration with Genentech to Identify Features of Successful T-Cell Therapies for Oncology (2022). www.arsenalbio.com
- 2. PR Newswire. CellOrigin Biotech Announces Global Strategic Collaboration with Qilu Pharma to Develop “Off-the-Shelf” CAR-iMAC Cell Therapy (2022). www.prnewswire.com/news-releases/cellorigin-biotech-announces-global-strategic-collaboration-with-qilu-pharma-to-develop-off-the-shelf-car-imac-cell-therapy-301632749.html
- 3. Scribe Therapeutics. Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-based Cell Therapies for Cancer (2022). www.scribetx.com/press-release-scribe-therapeutics-announces-research-collaboration-with-sanofi-to-accelerate-breakthrough-crispr-based-cell-therapies-for-cancer/
- 4. Cellusion. Cellusion and Celregen, a member of Fosun Pharma, Enter into License Agreement of CLS001 (2022). https://cellusion.jp/news/en/790/
- 5. GenOway. Sigma-Aldrich and genOway expand their CRISPR/Cas9 strategic alliance (2022). www.genoway.com/about/news/2022/sigma-aldrich-and-genoway-expand-their-crispr-cas9-strategic-alliance.htm
- 6. Sierra Space. Sierra Space, UC San Diego Partner to Develop the First Stem Cell Research Institute in Space (2022). www.sierraspace.com/newsroom/press-releases/sierra-space-uc-san-diego-partner-to-develop-the-first-stem-cell-research-institute-in-space/
- 7. Selexis. Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders (2022). www.selexis.com/newsroom/selexis-and-neximmune-sign-service-agreement-to-advance-multiple-immunotherapies-targeting-rare-cancers-and-autoimmune-disorders
- 8. Emercell. Emercell and Cell-Easy Sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001 (2022). www.emercell.com/newsandevents
- 9. Bit.bio. New cell products for neurodegenerative disease (2022). www.bit.bio/news/launch-tdp-microglia
- 10. FUJIFILM Diosynth. FUJIFILM Diosynth Biotechnologies breaks ground on a USD 1.6 billion (11 billion Danish kroner) expansion in Hillerød, Denmark (2022). https://fujifilmdiosynth.com/about-us/press-releases/fujifilm-diosynth-biotechnologies-breaks-ground-on-a-usd-1-6-billion-11-billion-danish-kroner-expansion-in-hillerod-denmark/
- 11. Orca Bio. Orca Bio Expands Manufacturing Capabilities to Develop and Commercialize its Precision Cell Therapies (2022). https://orcabio.com/2022-09-08/
- 12. Takeda. Strengthening Healthcare Systems to Meet Patients' Need for Plasma-Derived Therapies (2022). www.takeda.com/newsroom/newsreleases/2022/strengthening-healthcare-systems-to-meet-patients-need-for-plasma-derived-therapies/
- 13. CARsgen. CARsgen Releases the First Clinical Batch of CAR T Cells from its RTP GMP Manufacturing Facility in North Carolina. https://portalvhds1fxb0jchzgjph.blob.core.windows.net/press-releases-attachments/1444583/HKEX-EPS_20220901_10415190_0.PDF
- 14. CellResearch Corporation. CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte® (2022). www.cellresearchcorp.com/positive-results-of-corlicyte-phase-i-study
- 15. NCT04104451. Phase 1, Open-Label Safety Study of Umbilical Cord Lining Mesenchymal Stem Cells (Corlicyte®) to Heal Chronic Diabetic Foot Ulcers (2022). https://clinicaltrials.gov/ct2/show/NCT04104451
- 16. Immunis. Immunis Initiates Patient Enrollment for Muscle Atrophy Phase 1/2a Clinical Trial (2022). https://immunisbiomedical.com/news-media/press-releases/immunis-initiates-patient-enrollment-for-muscle-atrophy-phase-1-2a-clinical-trial/
- 17. Reversal of deficits in aged skeletal muscle during disuse and recovery in response to treatment with a secrotome product derived from partially differentiated human pluripotent stem cells. Geroscience 43, 2635–3652 (2021).
- 18. NCT05211986. Safety and Tolerability of IMM01-STEM in Patients with Muscle Atrophy Related to Knee Osteoarthritis (2022). https://clinicaltrials.gov/ct2/show/NCT05211986
- 19. Celyad. Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction (2022). https://celyad.com/2022/09/20/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction/
- 20. AVROBIO. AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial (2022). https://investors.avrobio.com/news-releases/news-release-details/avrobio-announces-neuronopathic-mucopolysaccharidosis-type-ii
- 21. AVROBIO. AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis (2022). https://investors.avrobio.com/news-releases/news-release-details/avrobio-receives-rare-pediatric-disease-designation-us-food-and
- 22. Bluebird bio. bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD) (2022). https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-receives-fda-accelerated-approval-skysonar-gene#
- 23. PR Newswire. Federal judge enters judgment in favor of Cell Surgical Network, ending lawsuit brought by the FDA (2022). www.prnewswire.com/news-releases/federal-judge-enters-judgment-in-favor-of-cell-surgical-network-ending-lawsuit-brought-by-the-fda-301616731.html
- 24. Immusoft. Immusoft Announces FDA Clearance of IND Application for ISP-001 for MPS I, the First Engineered B Cell Therapy to Enter into Clinical Trials (2022). www.immusoft.com/2022/09/01/immusoft-announces-fda-clearance-of-ind-application-for-isp-001-for-mps-i-the-first-engineered-b-cell-therapy-to-enter-into-clinical-trials/
- 25. Intellia Therapeutics. Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema (2022). https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-receives-us-fda-orphan-drug-designation-1
- 26. NCT05120830. NTLA-2002 in Adults with Hereditary Angioedema (HAE) (2022). https://clinicaltrials.gov/ct2/show/NCT05120830
- 27. Intellia. Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) (2022). https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-positive-interim-clinical-data
- 28. Kite Pharma. Kite's CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL) (2022). www.kitepharma.com/news/press-releases/2022/9/kites-car-t-cell-therapy-tecartus-granted-european-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-acute-lymphoblastic-leukemia
- 29. Kite Pharma. Kite's CAR T-cell Therapy Yescarta First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma (2022). www.kitepharma.com/news/press-releases/2022/9/kites-car-t-cell-therapy-yescarta-first-in-europe-to-receive-positive-chmp-opinion-for-use-in-second-line-diffuse-large-b-cell-lymphoma-and-high-gra
- 30. NCT03391466. Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7) (2022). https://clinicaltrials.gov/ct2/show/NCT03391466
- 31. Legend Biotech. CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (2022). https://legendbiotech.com/legend-news/carvykti-ciltacabtagene-autoleucel-receives-approval-from-japans-ministry-of-health-labour-and-welfare-mhlw-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-my/
- 32. Neuroplast. Neuroplast receives second orphan medicinal product designation for Neuro-Cells®, paving the way for application to both chronic and trauma-induced neurodegenerative diseases (2022). www.neuroplast.com/_files/ugd/6064f5_f04c8fbeedfd494885e0eeeb11d391f1.pdf
- 33. Arsenal Biosciences. Arsenal Biosciences Closes $220 Million Series B Financing to Advance Programmable Cell Therapy Programs into Clinical Development (2022). www.arsenalbio.com
- 34. . Starry syndicate powers $165M bet on in vivo CAR-T therapies, enabling Penn spinout Capstan to set sail. Fierce Biotech (2022). www.fiercebiotech.com/biotech/starry-syndicate-powers-165m-bet-vivo-car-t-therapies-enabling-penn-spinout-capstan-set
- 35. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91–96 (2022).
- 36. BioSpace. $1m MRFF Grant Awarded to Fund Investigation of Cynata's MSCs as a Treatment for Heart Disease (2022). www.biospace.com/article/-1m-mrff-grant-awarded-to-fund-investigation-of-cynata-s-mscs-as-a-treatment-for-heart-disease/
- 37. Marker Therapeutics. Marker Therapeutics Awarded $2 Million Grant from U.S. FDA To Support Marker's Phase 2 Artemis Trial of MT-401 in Post-Transplant AML (2022). https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-awarded-2-million-grant-us-fda-support
- 38. Matrigenix. Matregenix Announces Phase 1 SBIR Grant Award from National Institutes of Health (2022). https://matregenix.com/news/matregenix-announces-phase-1-sbir-grant-award-from-national-institutes-of-health%ef%bf%bc/